RESI Boston Returns September 21-23

9 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

More than two years following the last in-person RESI event, Life Science Nation is pleased to announce that RESI returns to an in-person format September 21-22 at the Westin Copley in Boston, MA. September 23 is a day dedicated to digital partnering for virtual and in-person attendees to take advantage of. Since the virtual shift, RESI has navigated the digital world and grown but remains dedicated to its mission: to connect early-stage startups in life science and healthcare with investors and licensing partners who are a fit for their product and stage of development.

The team behind RESI has learned much about what the community looks for in reliable, high-quality partnering, and looks forward to providing invaluable content with convenient and dynamic partnering options, which include both in-person (September 21-22) and virtual (September 23) options. In-person attendees can expect two days of active partnering, interactive panels, educational workshops, and live pitch sessions. Virtual attendees can still benefit from access to content recordings, as well as a single day dedicated exclusively to digital partnering.

We hope you’ll join us and continue to add value to the vibrant RESI community. Registration for RESI Boston is now open! Super early bird rates apply until July 1. Sign up today and save $500!

Register-now-button-new

RESI-Boston-2022-Banner - new - 1100px

Digital RESI June and the Future of Virtual Partnering

9 Jun

By Karen Deyo, Director of Investor Research, Israel BD, LSN

As we reach the end of Digital RESI June, we look forward to RESI Boston and Life Science Nation (LSN)’s first in-person event since January 2020, we are very proud of what we have been able to accomplish in making our virtual events a success. Like all our virtual events, this RESI’s attendees represented LSN’s global ecosystem, with startups and investors from 30 countries and 5 continents. LSN’s offerings have continued to evolve to meet the needs of the early-stage life science ecosystem with the introduction of the Audience Access pass, allowing the earliest stage startups to benefit from the experience and expertise of our investor panels and expert workshops before jumping into their own fundraising campaigns.

While we are all excited to be going back to in person events, the last two years have taught us that virtual partnering is here to stay, and that there will be a new normal for events moving forward. Startups and investors will have the flexibility to decide when they want to make the effort to attend events in person but will still be able to partner multiple times a year even if their schedule will not allow them to travel to every RESI.

We look forward to our next evolution of RESI, and hope that you will join us in person (September 21-22) or virtually (September 23) for RESI Boston!

Register-now-button-new

RESI-Boston-2022-Banner - new - 1100px

Massachusetts Medical Device Development Center (M2D2) Upcoming Events

9 Jun

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) is proud to be long-term tech hub partners with the Massachusetts Medical Device Development Center (M2D2). Get involved with M2D2’s upcoming free events geared at setting startups up for success through their IMPACT Accelerator Program. M2D2’s IMPACT Accelerator program is a 12-week accelerator that helps startups bring their technology closer to market.

Learn how to initiate strategic partnerships, valuable networking and more at next Thursday’s M2D2’s CAPCaT Big Company/Little Company Showcase! For the third year in a row, the UMass CAPCaT program will present a high-energy, high-value event highlighting six breakthrough PoCT startups who have utilized CAPCaT funding to advance their solution.

https___cdn.evbuc.com_images_300247419_209363275440_1_original

M2D2 IMPACT logo-transparentTen startups have been working with M2D2 and their Cycle 3 Sponsor Hologic to advance the commercialization of their innovation through the IMPACT Accelerator Program. Join M2D2’s early-stage women’s health medical device startups at the onsite M2D2 IMPACT Accelerator Pitch-Off on July 20. While applications are closed, M2D2 invites all medtech and femtech startups to attend to learn more about the latest innovations in these areas. The Pitch-Off takes place at M2D2 headquarters in Lowell, MA. Meet the finalists and learn more here.

UPDATED-IMPACT-Cycle3-Social

LSN Vice President of Business Development, Candice He will be presenting an award on behalf of the community of early-stage investors, entrepreneurs, and service providers that regularly pitch and participate at RESI partnering events. LSN is pleased to award a premier registration and pitch slot at the upcoming RESI Boston, September 21-22 at Westin Copley, with a third day of dedicated digital partnering on September 23. Originally valued at $2,995, the award includes a 3-day registration with the premier partnering upgrade and a guaranteed spot to pitch at the Innovator’s Pitch Challenge. Sign up for RESI Boston at super early bird rates and get involved with the RESI network today!

RESI-Boston-2022-Banner - new - 1100px

Hot Investor Mandate: PE Firm With China Offices Invests Up to $20M in Late-Stage Therapeutic Assets and Other Technologies Close to Commercialization

9 Jun

A private equity firm with offices China makes late venture and growth stage investments exclusively in the life sciences and has invested in nearly 50 companies to date. The firm’s target investment size is USD 15-20 million per company and typically USD 5 million for cross-border investments. The firm primarily focuses on opportunities in China; however the firm is also interested in companies abroad that have a strong China angle or China strategy in near term (target market, R&D/manufacturing, sales, etc). The firm is actively seeking new investment opportunities.

The firm seeks to invest in late-stage assets that are on market or close to commercialization. The firm is interested in therapeutics/pharmaceuticals, medical devices, diagnostics, and healthcare services. For therapeutics, the firm will consider small molecules and biologics as well as biosimilars and reformulated drugs. At minimum, the product should be in Phase III of clinical trials. The firm may look at Phase II candidates that have a relatively less complicated clinical trial. For example, the firm will not consider biologics in Phase II. For indications, the firm focuses on products that address a large unmet medical need in China. This includes diabetes, cardiovascular, cerebrovascular, liver, and degenerative diseases. For medical devices, the firm is opportunistic in terms of subsectors. Similar to therapeutics, the firm focuses on indications relevant to China. The firm looks for devices that are very close to market or market approved.

The firm is only interested in companies that have a strong China angle or strategy. The firm typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Europe-Based Family Office Invests in Devices & Digital Health Companies in High Unmet Medical Need Areas Including CNS, Ophthalmology, Chronic Diseases, Etc.

9 Jun

A family office based in Europe invests in healthcare and technology companies, and seeks to partner with awesome entrepreneurs who are transforming healthcare – solving big problems and creating great companies. Typical investment is $200k-1M and the firm seeks to invest globally.

The firm‘s interests include chronic eye diseases, diabetes, Parkinson’s, Alzheimer’s, AI-enabled breast cancer detection, stroke, chronic kidney disease, digital health, medical devices, telemedicine. The firm does not actively review opportunities in therapeutics at this time.

The firm partners with resourceful entrepreneurs who have proven their ability to get results.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Clinical-Stage Biopharmaceutical Company Seeks to Partner with Early-Stage Pre-Clinical to Early Clinical Stage Therapeutics in Oncology, Ophthalmology, and More

9 Jun

A clinical stage biopharmaceutical company with multiple offices in China and USA is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing, and is currently developing nine therapeutic antibody molecules targeting multiple indications. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.

The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare-Focused Venture Fund Looks for USA-Based Companies with Strong Interest in Platform Technologies and Drug Development-Enabling Technologies

9 Jun

An early-stage healthcare venture fund established in 2018 with USA-based teams looks to invest in companies and teams with novel approaches in both the life sciences and Bio-IT sector.

The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Bio-IT sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow.

The firm is actively looking for companies from Seed to Series A and is focused on the US with select opportunities globally.

The firm is focused on two main investment themes:

(1) Life Sciences – The firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and immune based disease. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;

(2) Bio IT – Bio IT is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery / development (proteomics and metabolomics), and new solutions to improve the efficiency of new modalities (i.e., cell therapy manufacturing, gene therapy carries, etc.).

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →